| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 1,339 | 670 | 755 | 795 |
| Depreciation and amortization | 351 | 365 | 342 | 336 |
| Deferred and prepaid income taxes | -351 | -22 | 69 | -90 |
| Stock-based compensation expense | 83 | 71 | 79 | 75 |
| Goodwill and other intangible asset impairment charges | NaN | 0 | 0 | 46 |
| Net loss (gain) on investments and notes receivable | 158 | -42 | -10 | 219 |
| Contingent consideration net expense (benefit) | -30 | 7 | 11 | -5 |
| Inventory step-up amortization | 2 | 5 | 9 | 37 |
| Fixed asset and right-of-use asset impairment | NaN | 51 | 73 | NaN |
| Other, net | 27 | 20 | -50 | 79 |
| Trade accounts receivable | 117 | 98 | 32 | 32 |
| Inventories | 177 | 50 | 94 | -65 |
| Other assets | 109 | -18 | -5 | 31 |
| Accounts payable, accrued expenses and other liabilities | -512 | 285 | 165 | 231 |
| Cash provided by (used for) operating activities | 348 | 1,364 | 1,343 | 1,286 |
| Purchases of property, plant and equipment and internal use software | 177 | 351 | 181 | 157 |
| Payments for acquisitions of businesses, net of cash acquired | 523 | 89 | 256 | 1,009 |
| Proceeds from (payments for) investments and acquisitions of certain technologies | -61 | 74 | 70 | 33 |
| Proceeds for settlements of hedge contracts | NaN | NaN | 0 | 69 |
| Other, net | -48 | -73 | -4 | -4 |
| Cash provided by (used for) investing activities | -591 | -512 | -502 | -1,126 |
| Payment of contingent consideration previously established in purchase accounting | NaN | 0 | 0 | 62 |
| Payments for finance leases | 0 | 209 | 7 | 6 |
| Payments on short-term borrowings | 259 | 0 | 12 | 500 |
| Net increase (decrease) in commercial paper | 0 | 0 | -4 | NaN |
| Proceeds from long-term borrowings, net of debt issuance costs | 0 | 0 | 0 | 0 |
| Cash used to net share settle employee equity awards | 85 | 3 | 5 | 5 |
| Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans | 81 | 20 | 115 | 32 |
| Other, net | 3 | 9 | -1 | -1 |
| Cash provided by (used for) financing activities | -260 | -184 | -104 | -340 |
| Effect of foreign exchange rates on cash | 0 | 3 | -2 | 2 |
| Net increase (decrease)in cash, cash equivalents, restricted cash and restricted cash equivalents | -504 | 671 | 735 | -179 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 2,147 | 1,476 | 741 | 919 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | 1,643 | 2,147 | 1,476 | 741 |
BOSTON SCIENTIFIC CORP (BSX)
BOSTON SCIENTIFIC CORP (BSX)